Daily Management Review

Pfizer and BioNTech vaccines may be admitted to the market in October


Germany will conduct clinical trials of a COVID-19 coronavirus vaccine developed by the German BioNTech and the American Pfizer Inc. If the trials are successful, the companies plan to apply for the vaccine on the market in October.

The Paul Ehrlich Institute has already approved the corresponding tests of the so-called second and third phases, Deutsche Welle reports.

The trials in Germany will be part of an international study that began in July. It is planned that up to 30 thousand volunteers will participate in it, who will receive a vaccine or a placebo. Now 25 thousand volunteers in 120 research centers around the world have already taken part in clinical trials.

“Large, controlled phase 3 trials are essential to definitively confirming the safety and efficacy of the vaccine,” BioNTech co-founder Ugur Sahin said Monday.

If the vaccine is admitted to the market, it is planned to release up to 100 million doses by the end of this year, and in 2021 it is planned to produce more than 1.3 billion doses.

Pharmaceutical and biotech companies around the world are working to develop a vaccine for the coronavirus. In Germany, the biotech company CureVac began to conduct clinical trials earlier.

source: dw.de